ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,013.13
      -1.71%
      US Tech 100
      21,145.20
      0.48%
      Dow Jones
      43,428.02
      -1.69%
      Brent Oil
      74.185
      0.11%
      Bitcoin
      95,866.82
      -0.42%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. UK
      5. LSE

      6. Myriad Genetics Inc (0K3W) Quote

      Myriad Genetics Inc

      Myriad Genetics Inc (0K3W)

      LSE
      35.68
      0.00
      ( 0.00% )
      Updated: 19:00:00
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      35.68
      Bid
      0.00
      Ask
      0.00
      Volume
      0.00
      0.00 Day's Range 0.00
      35.68 52 Week Range 35.68
      Market Cap
      2.933B
      Previous Close
      35.68
      Open
      -
      Last Trade
      (O)
      Last Trade Time
      -
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      379
      Shares Outstanding
      82,198,000
      Dividend Yield
      -
      PE Ratio
      -4.43
      Earnings Per Share (EPS)
      -3.2
      Revenue
      753.2M
      Net Profit
      -263.3M

      About Myriad Genetics Inc

      Sector
      In Vitro,in Vivo Diagnostics
      Industry
      In Vitro,in Vivo Diagnostics
      Website
      www.myriad.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Myriad Genetics Inc is listed in the In Vitro,in Vivo Diagnostics sector of the London Stock Exchange with ticker 0K3W. The last closing price for Myriad Genetics was $35.68. Over the last year, Myriad Genetics shares have traded in a share price range of $ 35.68 to $ 35.68.

      Myriad Genetics currently has 82,198,000 shares outstanding. The market capitalization of Myriad Genetics is $2.93 billion. Myriad Genetics has a price to earnings ratio (PE ratio) of -4.43.

      Ask ADVFN Intelligence (AI)

      0K3W Latest News

      More News
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10035.6835.6835.6820635.68DE
      40035.6835.6835.6819135.68DE
      120035.6835.6835.6837935.68DE
      260035.6835.6835.6841035.68DE
      520035.6835.6835.6827035.68DE
      1560035.6835.6835.6812135.68DE
      2600035.6835.6835.688335.68DE

      0K3W - Frequently Asked Questions (FAQ)

      What is the current Myriad Genetics share price?
      The current share price of Myriad Genetics is $ 35.68
      How many Myriad Genetics shares are in issue?
      Myriad Genetics has 82,198,000 shares in issue
      What is the market cap of Myriad Genetics?
      The market capitalisation of Myriad Genetics is USD 2.93B
      What is the 1 year trading range for Myriad Genetics share price?
      Myriad Genetics has traded in the range of $ 35.68 to $ 35.68 during the past year
      What is the PE ratio of Myriad Genetics?
      The price to earnings ratio of Myriad Genetics is -4.43
      What is the cash to sales ratio of Myriad Genetics?
      The cash to sales ratio of Myriad Genetics is 1.55
      What is the reporting currency for Myriad Genetics?
      Myriad Genetics reports financial results in USD
      What is the latest annual turnover for Myriad Genetics?
      The latest annual turnover of Myriad Genetics is USD 753.2M
      What is the latest annual profit for Myriad Genetics?
      The latest annual profit of Myriad Genetics is USD -263.3M
      What is the registered address of Myriad Genetics?
      The registered address for Myriad Genetics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Myriad Genetics website address?
      The website address for Myriad Genetics is www.myriad.com
      Which industry sector does Myriad Genetics operate in?
      Myriad Genetics operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      EPPEnergypathways Plc
      7.75p
      (38.39%)
      		10.08M
      PETPetrel Resources Plc
      1.90p
      (26.67%)
      		1.06M
      CLACelsius Resources Limited
      0.60p
      (20.00%)
      		3.3M
      CDLCloudbreak Discovery Plc
      0.125p
      (19.05%)
      		3.55M
      UKRUkrproduct Group Limited
      4.00p
      (17.65%)
      		3
      NARFNarf Industries Plc
      0.275p
      (-21.43%)
      		1.35M
      SYNSynergia Energy Ltd
      0.0305p
      (-16.44%)
      		42.78M
      ALNAAlina Holdings Plc
      7.00p
      (-12.50%)
      		746
      ALBAAlba Mineral Resources
      0.0175p
      (-12.50%)
      		54.87M
      TLYTotally Plc
      3.20p
      (-12.33%)
      		4.93M
      SYMESupply@me Capital Plc
      0.0044p
      (14.29%)
      		513.42M
      TRPTower Resources Plc
      0.027p
      (-1.82%)
      		402.6M
      NTVONativo Resources Plc
      0.0015p
      (0.00%)
      		209.46M
      UKOGUk Oil & Gas Plc
      0.012p
      (0.00%)
      		180.7M
      CORCorpus Resources Plc
      0.0155p
      (-8.82%)
      		65.86M

      Discussion

      View Full Feed
      manibiotech manibiotech 1 minute ago
      Agree 
      At the end of the day it's the court's opinion that counts and matters . Hopefully Wood may do something more favorable .
      But eventually whatever court rules is the bottom line . One can write their personal opinions here all they want , it is meaningless and inconsequential . 
      NWBO
      ksquared ksquared 2 minutes ago
      Covergirl...
      What a beast.
      https://nypost.com/wp-content/uploads/sites/2/2025/02/FEBRUARY24.P1_LCF.jpg?resize=400,441&quality=90&strip=all&w=750
      Investor082 Investor082 2 minutes ago
      Nope. No hiring & No reimbursement tells you all you need to know. They will be diluting endlessly in penny land. No big pharma will provide non dilutive funds. Forget about major institutional investors. This management has done nothing but lost money of investors for 10-12 years. No one is going t
      NWBO
      glenn1919 glenn1919 3 minutes ago
      ORIS................................https://stockcharts.com/h-sc/ui?s=ORIS&p=W&b=5&g=0&id=p86431144783#google_vignette
      ORIS
      Monksdream Monksdream 3 minutes ago
      Top 15 at 6:50
      Same Asian tickers from Friday night


      https://ih.advfn.com/markets/nasdaq/premarket
      Monksdream Monksdream 3 minutes ago
      Top 15 at 6:50
      Same Asian tickers from Friday night


      https://ih.advfn.com/markets/nasdaq/premarket
      FeMike FeMike 3 minutes ago
      What a huge wall of utterly worthless garbage.

      This isn’t happening. Just stop.
      NWBO
      glenn1919 glenn1919 5 minutes ago
      reto...............................https://stockcharts.com/h-sc/ui?s=RETO&p=W&b=5&g=0&id=p86431144783#google_vignette
      RETO
      PutzMueler PutzMueler 7 minutes ago
      Dan’s chart

      thanks Daniel D.


      A lot to digest
      https://stockcharts.com/sc3/ui/?s=NB

      Flag, Golden Cross, long legged Doji, below 20 DMA but above $2.20 support.

      Should see market sentiment
      News would be nice soon.
      NB
      Jake731 Jake731 7 minutes ago
      Good morning all. 





      TPTW……!!!!!!!
      TPTW
      glenn1919 glenn1919 7 minutes ago
      STEC..............................weeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
      STEC
      RealDutch RealDutch 9 minutes ago
      I don't expect them to deliver today. The probability is close to 0.1%
      ITUP
      dennisdave dennisdave 10 minutes ago
      Does Advent do any work for NWBO that requires compensation? No idea but certainly of such magnitude that it accounts for ALL of Advents costs including the 84 staff.

      There is a high cost to provide compassionate care batches for patients, to do process improvement activities such a
      NWBO
      dmb2 dmb2 14 minutes ago
      Your interpretation is a baseless allegation. Toucan owns Advent but NW owns the facility, good thing most real investors here know the difference between informed and baseless posters such as yourself.

      The significant time it has taken has also been discussed at length. This underta
      NWBO
      Investor2014 Investor2014 15 minutes ago
      Bot template nonsense!
      AVXL
      Real McCoy Real McCoy 16 minutes ago
      You’re out 100% and were proven wrong.

      That’s it.
      work-n-hard work-n-hard 17 minutes ago
      NIXX: Checked this one out last night and have it on watch. ✅️
      NIXX
      dennisdave dennisdave 17 minutes ago
      I understand, and I'm sure the magistrate is doing his best to remain fair and impartial. Despite that, however, so you put more value on Posner's arguments than the magistrate's findings. If you value your own opinion over that of a judge then you demonstrate being incapable of really observing imp
      NWBO
      valuemind valuemind 17 minutes ago
      I sold META (FB at that time) at about $35 at the first time, and then at about 150, for the nice profit. I felt very smart to predict its revenue and earning growth at the time. In the end, I not only missed the fast boat, but also paid tax on realized capital gain. As a result, I accept I am not g
      docj docj 19 minutes ago
      MGK_2
      •
      9h ago
      "Hope Rugo’s TNBC Nuke (UCSF): She ran leronlimab with carboplatin in 2019—stable disease at ASCO 2020. January 15 news says her 2025 TNBC basket trial’s live. Her bio whispers “CCR5 research”—leronlimab in there? It’s a sleeper atom bomb. Rugo’s a cancer titan; t
      CYDY
      docj docj 20 minutes ago
      MGK_2
      •
      9h ago
      "Hütter’s Legacy Reload (Germany): Gero Hütter’s Berlin Patient cure—CCR5-delta 32 king, SAB relic. His 2008 win powers LATCH—a murmur from him flips HIV upside down."

      "In September 2020, CytoDyn had this press release: https://www.globenewswire.com
      CYDY
      docj docj 20 minutes ago
      MGK_2
      •
      9h ago
      "Montefiore’s Neuro Bet: Beyond oncology, the Einstein/Montefiore preclinicals (March 2024) and Cornell’s Alzheimer’s pilot (December 2024) hint at CCR5’s brain inflammation role. A neurodegeneration win’s a $50B market—CYDY’s dark pool."

      "27:15 Nad
      CYDY
      sctts sctts 21 minutes ago
      $$$ Today is the Day $$$$

      $$$$ $FRX $$$
      FRX
      misterfishman misterfishman 21 minutes ago
      Soon I hope.
      RDAR
      misterfishman misterfishman 22 minutes ago
      True that my big bro. I think peeps are holding this expecting big new soon .this is after all a way under valued 100 mill and counting RM in the making when its all said and done this could be a billion dollar stock we buy for subpennies now that is nuts if all of it is true.
      IGPK

      Your Recent History

      LSE
      0K3W
      Myriad Genetics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads